Chinook Therapeutics Inc Cvr (ADRO)
EBITDA Growth
31.31%
TTM · Period ending:
ADRO EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported31.31%period ending
Latest reported31.31%period ending
ADRO TTM EBITDA YoY % (-56.68% → 31.31%)
Year-over-year change
High-resolution chart · PNG
ADRO ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 31.3081% | |
| 22.0862% | |
| 25.0591% | |
| 12.3548% | |
| 5.2359% | |
| 9.8626% | |
| 2.9044% | |
| 8.1174% | |
| 5.0874% | |
| -5.1563% | |
| -46.1535% | |
| -47.8326% | |
| -140.5136% | |
| -450.2538% | |
| -39.1401% | |
| -73.9847% | |
| 13.5743% | |
| 66.4106% | |
| -56.6816% |